首页 | 本学科首页   官方微博 | 高级检索  
检索        

冠心宁片对大鼠心肌缺血再灌注损伤的保护作用研究
引用本文:胡飞,戎亦骊,朱科燕,陆红,陈诚,陈民利,潘永明.冠心宁片对大鼠心肌缺血再灌注损伤的保护作用研究[J].中国比较医学杂志,2017,27(5):76-82.
作者姓名:胡飞  戎亦骊  朱科燕  陆红  陈诚  陈民利  潘永明
作者单位:浙江中医药大学比较医学研究所, 杭州 310053;浙江省医疗器械检验院, 杭州 310018,浙江中医药大学比较医学研究所, 杭州 310053,浙江中医药大学比较医学研究所, 杭州 310053,浙江中医药大学比较医学研究所, 杭州 310053,浙江中医药大学比较医学研究所, 杭州 310053,浙江中医药大学比较医学研究所, 杭州 310053,浙江中医药大学比较医学研究所, 杭州 310053
基金项目:浙江中医药大学比较医学创新团队(XTD201301)。
摘    要:目的观察冠心宁片(GXNT)对心肌缺血再灌注损伤(MI/RI)大鼠心肌梗死和心脏自主神经功能的影响。方法 SD大鼠70只,随机分为7组,即伪手术组、MI/RI组、GXNT 75 mg/kg,150 mg/kg,300 mg/kg,600mg/kg剂量组和300 mg/kg复方丹参片(DST)组,每组10只。所有大鼠均预防性经口灌胃给药7 d后,采用结扎大鼠左冠状动脉前降支法,建立MI/RI大鼠模型。期间记录大鼠心电图并分析心电图J点和心率变异性(HRV)指标,并用伊文思蓝(EB)和2,3,5-氯化三苯基四氮唑蓝(TTC)双重染色心肌并分析心肌梗死面积以及行HE染色观察心肌病理学改变,测定血浆乳酸脱氢酶(LDH)、肌酸激酶(CK)、丙二醛(MDA)和一氧化氮(NO)水平。结果与MI/RI组比,冠心宁片组和复方丹参片组能明显减轻心肌梗死面积和抑制LDH和CK活性的升高(P0.05,P0.01),并能降低再灌注期大鼠"-J值和J点平均值(P0.05,P0.01),显著提高HRV和血浆NO水平以及降低血浆MDA含量(P0.05,P0.01),并能改善心肌组织病理。结论冠心宁片能减轻MI/RI大鼠心肌梗死,并能改善心脏自主神经功能。

关 键 词:冠心宁片  心肌缺血再灌注损伤  心脏自主神经功能  心肌梗死  大鼠
收稿时间:2016/9/27 0:00:00

Study on the protective effect of Guanxinning Tablet on myocardial ischemia reperfusion injury in rats
HU Fei,RONG Yi-li,ZHU Ke-yan,LU Hong,CHEN Cheng,CHEN Min-li and PAN Yong-ming.Study on the protective effect of Guanxinning Tablet on myocardial ischemia reperfusion injury in rats[J].Chinese Journal of Comparative Medicine,2017,27(5):76-82.
Authors:HU Fei  RONG Yi-li  ZHU Ke-yan  LU Hong  CHEN Cheng  CHEN Min-li and PAN Yong-ming
Institution:Institute of Comparative Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China;Zhejiang Institute for the Control of Madical Device, Hangzhou 310018,Institute of Comparative Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China,Institute of Comparative Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China,Institute of Comparative Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China,Institute of Comparative Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China,Institute of Comparative Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China and Institute of Comparative Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China
Abstract:Objective To observe the effect of Guanxinning Tablet (GXNT) on myocardial infarction and cardiac autonomic nervous function in rats with myocardial ischemia reperfusion injury (MI/RI). Methods Seventy SD rats were divided into 7 groups randomly (n=10); the sham group, the MI/RI group, 75 mg/kg, 150 mg/kg, 300 mg/kg and 600 mg/kg GXNT groups and 300 mg/kg Compound Danshen Tablets (DST) group. All rats were administered orally for 7 days, and then the MI/RI model was made by ligating the left anterior descending branch of coronary artery in rats. The changes of electrocardiogram were recorded and the electrocardiogram of J points and heart rate variability (HRV) parameters were analyzed. At the end of reperfusion, the myocardial infarct size was measured by using Evans blue and tetrazolium chloride (TTC) double staining, and pathological changes of myocardium were observed by HE staining. The changes of serum lactate dehydrogenase (LDH), creatine kinase (CK), malondialdehyde (MDA) and nitric oxide (NO) levels were also detected. Results Compared with MI/RI group, GXNT and DST groups were significantly reduced myocardial infarct size and inhibited the rising of serum LDH and CK activities (P< 0.05, P< 0.01), and also reduced the total or average value of J point during reperfusion (P< 0.05, P< 0.01). Meanwhile, GXNT and DST groups were markedly increased HRV and serum NO level as well as decreased serum MDA content (P< 0.05, P< 0.01), and improved myocardial tissue pathology. Conclusions GXNT can reduce the myocardial infarction in rats with MI/RI, and also improve the cardiac autonomic nervous function.
Keywords:Guanxinning Tablet  Myocardial ischemia reperfusion injury  Cardiac autonomic nervous function  Myocardial infarction  Rats
本文献已被 CNKI 等数据库收录!
点击此处可从《中国比较医学杂志》浏览原始摘要信息
点击此处可从《中国比较医学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号